SLC5A2 and inherited lipid metabolism disorder: At baseline, significantly more patients in group 1 of Taiyuan used sodium-glucose cotransporter-2 inhibitors (SGLT-2i), angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), statins and dyslipidaemia therapy than in group 1 of Beijing.